Year Ahead Could Prove Rough For Private Biotech Financing
Financing Forecast: Industry Experts Have Grim Outlook For Private Biotechs
The second half of 2022 saw a downturn in fundraising by venture capital firms, and panelists at BIO CEO said that could spell trouble in 2023.
You may also be interested in...
An economist told Scrip that banks could become more cautious about handing out loans to biotech start-ups, driving more M&A in the sector.
Investment bank analysts, VC funds and biopharma companies all sought to calm investors’ nerves as a go-to financial institution for tech and biotech collapsed.
Early-stage companies need to be more flexible on the financing terms they are willing to accept and in finding ways to gather evidence to support the impact of their products or services.